AKT1 and Hyperglycemia: The incidence of hyperglycemia of any grade in clinical trials of AKT inhibitors varies broadly, going from 92% with MK-2206 and anastrozole to 4% with ipatasertib and paclitaxel (Ma et al., 2016; Oliveira et al., 2019).